Johnson & Johnson (JNJ): Price and Financial Metrics
GET POWR RATINGS... FREE!
JNJ POWR Grades
- Stability is the dimension where JNJ ranks best; there it ranks ahead of 95.22% of US stocks.
- The strongest trend for JNJ is in Momentum, which has been heading down over the past 31 weeks.
- JNJ ranks lowest in Momentum; there it ranks in the 11th percentile.
JNJ Stock Summary
- JNJ has a market capitalization of $453,418,123,797 -- more than approximately 99.72% of US stocks.
- Johnson & Johnson's stock had its IPO on January 1, 1986, making it an older stock than 92.76% of US equities in our set.
- In terms of volatility of its share price, JNJ is more volatile than merely 3.74% of stocks we're observing.
- Stocks that are quantitatively similar to JNJ, based on their financial statements, market capitalization, and price volatility, are JPM, WMT, NVDA, UNH, and MA.
- Visit JNJ's SEC page to see the company's official filings. To visit the company's web site, go to www.jnj.com.
JNJ Valuation Summary
- JNJ's price/sales ratio is 5.4; this is 50% higher than that of the median Healthcare stock.
- JNJ's EV/EBIT ratio has moved up 1.8 over the prior 243 months.
- Over the past 243 months, JNJ's price/sales ratio has gone down 0.7.
Below are key valuation metrics over time for JNJ.
JNJ Stock Price Chart Interactive Chart >
JNJ Price/Volume Stats
|Current price||$172.16||52-week high||$173.65|
|Prev. close||$172.18||52-week low||$133.65|
|Day high||$173.34||Avg. volume||7,474,285|
|50-day MA||$167.47||Dividend yield||2.46%|
|200-day MA||$159.75||Market Cap||453.37B|
Johnson & Johnson (JNJ) Company Bio
Founded in 1886, Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture, and sale of products in the healthcare field within its Consumer, Pharmaceutical and Medical Devices segments. The Consumer segment consists of skin and self-care product brand names such as Aveeno, Neutrogena, Rogaine, Tylenol, Motrin, Listerine, and Band-Aid. Johnson’s Pharmaceutical segment contains biopharma products that address immune, cardiovascular, metabolic, and infectious disease medical conditions. The Medical Device segment develops products centered around orthopedic, surgical, intervention, and vision solutions. The company has over 130,000 employees worldwide and is headquartered in New Brunswick, New Jersey. The company’s current Chief Executive Officer is Alex Gorsky.
JNJ Price Forecast Based on DCF Valuation
|Current Price||DCF Fair Value Target:||Forecasted Gain:|
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Johnson & Johnson. To summarize, we found that Johnson & Johnson ranked in the 33th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 56.17%. As for the metrics that stood out in our discounted cash flow analysis of Johnson & Johnson, consider:
- As a business, JNJ is generating more cash flow than 97.64% of positive cash flow stocks in the Healthcare.
- The business' balance sheet reveals debt to be 7% of the company's capital (with equity being the remaining amount). Approximately just 21.82% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- JNJ's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 43.42% of tickers in our DCF set.
|Terminal Growth Rate in Free Cash Flow||Return Relative to Current Share Price|
JNJ Latest News Stream
|Loading, please wait...|
JNJ Latest Social Stream
View Full JNJ Social Stream
Latest JNJ News From Around the Web
Below are the latest news stories about Johnson & Johnson that investors may wish to consider to help them evaluate JNJ as an investment opportunity.
(Bloomberg) -- A bankruptcy judge agreed to consider blocking Johnson & Johnson from putting billions of dollars in potential health claims into a unit that could file bankruptcy to resolve the liabilities.U.S. Bankruptcy Judge Laurie Silverstein ordered J&J to appear at a hearing Thursday afternoon to respond to a request from people who say they were harmed by the company’s baby powder. Those alleged victims claim J&J may use “corporate manipulations” to dump talc-related claims into a subsidi
A U.S. congressional panel has asked Johnson & Johnson to provide it all documents related to the company's plans to put its talc liabilities into bankruptcy, according to a letter sent on Wednesday and seen by Reuters. Democrat Raja Krishnamoorthi, chairman of the U.S. House of Representatives Committee on Oversight and Reform's subcommittee on economic and consumer policy, wrote that the panel is trying to learn how J&J's plans may affect people who have said they were harmed by the company's baby powder. Krishnamoorthi also asked J&J to turn over documents showing how much funding it would provide to the new entity.
Pfizer CEO is no stranger to risks, and hopes to repeat the company's COVID-19 success with an oral treatment.
A subcommittee of the U.S. House Committee on Oversight and Reform has asked Johnson & Johnson to show it all documents related to plans to put its talc liabilities into bankruptcy, according to a letter sent on Wednesday and seen by Reuters. Democrat Raja Krishnamoorthi, chairman of the subcommittee on economic and consumer policy, wrote that the subcommittee is trying to learn how J&J's plans to put its talc liabilities into bankruptcy may affect victims who claim they were harmed by the company's baby powder. Krishnamoorthi also asked that J&J turn over documents showing how much funding it would provide to the new entity.
Dr. Manish Garg, Emergency Medicine Physician & Co-Founder of World Academic Council of Emergency Medicine, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
JNJ Price Returns
|Ex-Dividend Date||Type||Payout Amount||Change|
|Loading, please wait...|